TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26109687

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 115

Group type: COMPARATOR
Intervention: Kyphoplasty vs Vertebroplasty
Number of subjects: 115
Study: 25301859

Group type: EXPERIMENTAL
Intervention: Women with severe aortic valve stenosis
Number of subjects: 1611

Group type: COMPARATOR
Intervention: Men with severe aortic valve stenosis
Number of subjects: 1611

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1611

Group type: COMPARATOR
Intervention: Men
Number of subjects: 1611
Study: 24082728

Group type: EXPERIMENTAL
Intervention: OHA + 50 mg elemental zinc as zinc sulphate supplementation for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: OHA alone
Number of subjects: 54
Study: 21148439

Group type: EXPERIMENTAL
Intervention: Very early and intensive mobilization group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard stroke unit care (Control)
Number of subjects: 71
Study: 18816492

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 17164695

Group type: EXPERIMENTAL
Intervention: Single-dose activated charcoal (SDAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-dose activated charcoal (MDAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No activated charcoal (NoAC)
Number of subjects: 0
Study: 12959631

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (placebo or standard treatment)
Number of subjects: 51
Study: 10922195

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (2% lidocaine, minimum of 5 doses, approximately 40 microL per dose)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia (3.5-5.5 mL of a combination of 0.75% bupivacaine hydrochloride, 2% lidocaine, and hyaluronidase)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 476

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 476
Study: 8786727

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneously)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg body weight intravenous bolus)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: L-arginine (50 g in 50 mL normal saline over 30 minutes)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 18
Study: 2199394

Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 78

Group type: COMPARATOR
Intervention: High dose polyoestradiol phosphate (160 mg i.m. monthly)
Number of subjects: 78
Study: 686549

Group type: EXPERIMENTAL
Intervention: Exercise for 1 hour three times a week
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sedentary group (Control)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Exercise vs Sedentary
Number of subjects: 18
Study: 30931665

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (90 seconds)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Early cord clamping (<30 seconds)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 128
Study: 30929591

Group type: EXPERIMENTAL
Intervention: Aerobic exercise treatment group (n = 21)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No-aerobic control group (n = 19)
Number of subjects: 40
Study: 28937828

Group type: EXPERIMENTAL
Intervention: Alfuzosin hydrochloride (AH)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride (TH)
Number of subjects: 63
Study: 24642450

Group type: EXPERIMENTAL
Intervention: Soy food frequency questionnaire
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Baseline isoflavone concentrations (genistein and daidzein)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Urine concentrations of isoflavones
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Weekly estimated intake of isoflavones
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Spearman's rank correlation coefficient
Number of subjects: 54
Study: 23079866

Group type: EXPERIMENTAL
Intervention: Variable resistance (15 × 1 repetition maximum)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Variable resistance (5 × 10 repetitions)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All loading protocols
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Variable resistance loadings
Number of subjects: 25
Study: 21605003

Group type: EXPERIMENTAL
Intervention: Heat exposure without vascular occlusion at temperatures of 32, 36, 38, or 40 °C for 6 minutes
Number of subjects: 20
Study: 19520448

Group type: EXPERIMENTAL
Intervention: 8 Gy single-dose RT
Number of subjects: 327

Group type: COMPARATOR
Intervention: 8 Gy x 2 RT
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Both RT schedules
Number of subjects: 327
Study: 16616994

Group type: EXPERIMENTAL
Intervention: Hydromorphone (HYD) doses of 12 mg and 24 mg IM
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pre-session supplements of HYD (12 mg or 24 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cocaine use prior to the experiment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Different FR/unit dose combinations
Number of subjects: 13
Study: 14872155

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study: 11323364

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg epidural S(+)‐ketamine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ropivacaine (10 mg/mL, 10‐20 mL)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine and ropivacaine
Number of subjects: 37
Study: 9150295

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: saline
Number of subjects: 48
Study: 8001898

Group type: EXPERIMENTAL
Intervention: Simultaneous monophasic shock waveforms with bidirectional lead configuration
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Simultaneous monophasic and biphasic waveforms with a fixed pulse duration of 6.3 ms
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Simultaneous monophasic and biphasic shocks with a constant tilt using undirectional lead configuration
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Biphasic and triphasic shock waveforms with a fixed pulse duration of 10 ms
Number of subjects: 86
Study: 3196888

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study: 31884870

Group type: EXPERIMENTAL
Intervention: Feedback device
Number of subjects: 203

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 203
Study: 31722259

Group type: EXPERIMENTAL
Intervention: Dyad training with physical and observational practice and inter‐trial dialogue
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dyad training with physical practice and dialogue without observation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dyad training with physical and observational practice without dialogue
Number of subjects: 40

Group type: COMPARATOR
Intervention: Individual practice control group
Number of subjects: 40
Study: 28343225

Group type: EXPERIMENTAL
Intervention: Vadadustat (240, 370, 500, or 630 mg once-daily for 6 weeks)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 93
Study: 26304864

Group type: EXPERIMENTAL
Intervention: Deferoxamine infusion
Number of subjects: 48
Study: 23545931

Group type: EXPERIMENTAL
Intervention: SkinMedica® Hyperpigmentation System (HQ-free)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Obagi Nu‐Derm System (HQ-based)
Number of subjects: 36
Study: 21171737

Group type: EXPERIMENTAL
Intervention: Augmented self-help
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard self-help
Number of subjects: 262

Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 262
Study: 19066101

Group type: EXPERIMENTAL
Intervention: Minimally-invasive surgery plus rtPA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 100
Study: 16880092

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal septal myocardial ablation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control subjects (12 healthy individuals)
Number of subjects: 16
Study: 12915013

Group type: EXPERIMENTAL
Intervention: Kit delivery and counseling (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Counseling without the kit (group 2)
Number of subjects: 100
Study: 10743877

Group type: EXPERIMENTAL
Intervention: Priming of a stress word
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive load conditions
Number of subjects: 0
Study: 8706772

Group type: EXPERIMENTAL
Intervention: Buffered sublingual captopril (12.5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Peroral captopril (administered with 100 ml of water)
Number of subjects: 6
Study: 1395644

Group type: EXPERIMENTAL
Intervention: Right brain-damaged patients (RBD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Left brain-damaged patients (LBD)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Blocked presentations
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Contralateral stimulus presentation
Number of subjects: 39
Study: 6143667

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg b.i.d.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 13
Study: 30561711

Group type: EXPERIMENTAL
Intervention: Investigational arms
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control arms
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Double-blind trials
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Open-label trials
Number of subjects: 51
Study: 29217088

Group type: EXPERIMENTAL
Intervention: Induction cisplatin (80 mg/m2) and docetaxel (75 mg/m2) for 3 cycles followed by surgery and adjuvant erlotinib for 12 months
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Induction cisplatin and docetaxel
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Adjuvant erlotinib
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Major pathologic response
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Complete pathologic response in mediastinal/hilar nodes
Number of subjects: 47
Study: 26763489

Group type: EXPERIMENTAL
Intervention: Ivabradine 2.5 mg BID
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg BID
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 25041182

Group type: EXPERIMENTAL
Intervention: Systemic doxycycline for 21 days
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 21153418

Group type: EXPERIMENTAL
Intervention: Inhibition of venous outflow from the exercised leg for 18 minutes by inflating a cuff around the thigh immediately following exercise.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control occasion with no inhibition of venous outflow.
Number of subjects: 6
Study: 19245075

Group type: EXPERIMENTAL
Intervention: hCG stimulation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Basal inhibin B levels
Number of subjects: 29
Study: 17086855

Group type: EXPERIMENTAL
Intervention: Occlusal splint (treated group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No splint (control group)
Number of subjects: 84
Study: 15205987

Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac daily
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 150 mg diclofenac daily
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 245
Study: 11449205

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 400 microg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide (BUD) 200 microg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 100 microg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 200 microg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 84 microg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled beclomethasone dipropionate or BUD
Number of subjects: 0
Study: 9412707

Group type: EXPERIMENTAL
Intervention: Improved case management for sexually transmitted diseases (STD) using the syndromic approach in rural health units.
Number of subjects: 12534

Group type: COMPARATOR
Intervention: Comparison community (no improved case management).
Number of subjects: 12534

Group type: EXPERIMENTAL
Intervention: Improved case management for STD.
Number of subjects: 12534
Study: 7522528

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatic‐intestinal and multivisceral transplantation
Number of subjects: 0
Study: 2890805

Group type: EXPERIMENTAL
Intervention: Vi capsular polysaccharide (CPS) vaccine (25 micrograms, single intramuscular injection)
Number of subjects: 11384
Study: 876669

Group type: EXPERIMENTAL
Intervention: 60 mg morphine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 60 mg codeine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 600 mg aspirin
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 30575287

Group type: EXPERIMENTAL
Intervention: Pupil expansion device
Number of subjects: 536

Group type: COMPARATOR
Intervention: No pupil expansion device
Number of subjects: 536
Study: 27885163

Group type: EXPERIMENTAL
Intervention: Arm Motor Ability Test (AMAT) intervention
Number of subjects: 146
Study: 26347971

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 80
Study: 23614336

Group type: EXPERIMENTAL
Intervention: Telemetric body weight measurement (TBWM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment without telemetric monitoring (Control Group)
Number of subjects: 120
Study: 22390033

Group type: EXPERIMENTAL
Intervention: Opening-window on thermoplastic mask (test group)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intact thermoplastic mask (control group)
Number of subjects: 73
Study: 19537368

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream (placebo)
Number of subjects: 20
Study: 17413098

Group type: EXPERIMENTAL
Intervention: Glucose supplemented with branched-chain amino acids (isoleucine, leucine, valine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose supplemented with leucine, isoleucine, valine, lysine, and threonine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whey protein drink
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference drink (pure glucose)
Number of subjects: 12
Study: 15138417

Group type: COMPARATOR
Intervention: Multi‐Test II
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IDT
Number of subjects: 40
Study: 11679990

Group type: EXPERIMENTAL
Intervention: Temporary portocaval shunt (PCS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No temporary portocaval shunt (no-PCS)
Number of subjects: 80
Study: 9080896

Group type: EXPERIMENTAL
Intervention: Q-switched ruby laser (694 nm)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Q-switched neodymium: YAG laser (1064 nm)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 5
Study: 8199752

Group type: EXPERIMENTAL
Intervention: Nocloprost clathrate (400 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (with and without equivalent amounts of beta-cyclodextrin)
Number of subjects: 15
Study: 3330992

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30-60 mg/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25-50 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29381560

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (3-g pill daily for 12 weeks, containing 1.8-g eicosapentaenoic acid and 1.2-mg docosapentaenoic acid)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (44.8 mg of high oleic safflower oil)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (specific to Kaposi sarcoma patients)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (specific to Kaposi sarcoma patients)
Number of subjects: 67
Study: 27317632

Group type: EXPERIMENTAL
Intervention: α1‐adrenergic blockade (oral Prazosin, 0.05 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26215644

Group type: EXPERIMENTAL
Intervention: Early, individually tailored occupational rehabilitation intervention using acceptance and commitment therapy dialogue and individual-placement-and-support-inspired tools.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with identical inclusion and exclusion criteria except for municipality of residence.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcome analysis of co-morbidity and socio-economic status as effect modifiers of the intervention effect on return to work.
Number of subjects: 0
Study: 24124710

Group type: EXPERIMENTAL
Intervention: ICP monitoring (Group A, B, C)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Group C (ICP monitoring)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Mannitol dosage in Groups A, B, C
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (no ICP monitoring)
Number of subjects: 216
Study: 20889295

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18339160

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA) using propofol and remifentanil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 18
Study: 16768051

Group type: EXPERIMENTAL
Intervention: Oral estradiol 2 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Transdermal estradiol 50 microg/day
Number of subjects: 45
Study: 15641867

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 to 80 mg b.i.d.
Number of subjects: 296

Group type: COMPARATOR
Intervention: Risperidone 3 to 5 mg b.i.d.
Number of subjects: 296
Study: 11384791

Group type: EXPERIMENTAL
Intervention: Benzodiazepines administered by paramedics
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control of status epilepticus prior to arrival at the emergency department
Number of subjects: 205
Study: 9454352

Group type: EXPERIMENTAL
Intervention: 4 x 3 Gy irradiation
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: 1 x 5 Gy irradiation
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: 1 x 7 Gy irradiation
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Indometacin for 7 days
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Indometacin for 14 days
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Acetyl salicyl acid (ASS) for 14 days
Number of subjects: 585

Group type: COMPARATOR
Intervention: Historical control group (no prophylactic therapy)
Number of subjects: 585
Study: 8508283

Group type: EXPERIMENTAL
Intervention: Ranitidine with NSAID continued
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Ranitidine with NSAID discontinued
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo with NSAID discontinued
Number of subjects: 149
Study: 3789787

Group type: EXPERIMENTAL
Intervention: Higher copper content formulas
Number of subjects: 145

Group type: COMPARATOR
Intervention: Lower copper content formulas
Number of subjects: 145
Study: 29769507

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (1μg/kg) with intravenous fentanyl (1μg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (1μg/kg) with intravenous fentanyl (1μg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous fentanyl (2μg/kg)
Number of subjects: 120
Study: 26865356

Group type: EXPERIMENTAL
Intervention: Short retention interval (RI) with reporting-error-sensitive measures (correspondence rate and inflation ratio)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Long retention interval (RI) with reporting-error-sensitive measures (correspondence rate and inflation ratio)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Breakfast location in classroom
Number of subjects: 480

Group type: COMPARATOR
Intervention: Breakfast location in cafeteria
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Lunch reports
Number of subjects: 480

Group type: COMPARATOR
Intervention: Breakfast reports
Number of subjects: 480
Study: 25058311

Group type: EXPERIMENTAL
Intervention: High-rosmarinic acid spearmint tea
Number of subjects: 62

Group type: COMPARATOR
Intervention: Commercially available spearmint tea
Number of subjects: 62
Study: 22037055

Group type: EXPERIMENTAL
Intervention: High genetic risk scenario
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Generic risk scenario
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Low genetic risk scenario
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 49
Study: 20797502

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary stents
Number of subjects: 0
Study: 17940147

Group type: EXPERIMENTAL
Intervention: Graded training program (13 weeks)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Standard training program (8 weeks)
Number of subjects: 532
Study: 16847231

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with simple sutured crura (nonmesh group, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication with prosthetic hiatal closure (mesh group, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (nonmesh and mesh)
Number of subjects: 40
Study: 12788263

Group type: EXPERIMENTAL
Intervention: Skills for Adolescence (SFA) program
Number of subjects: 7426

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 7426